Drug Makers Stocks Under Scanner -- Pfizer, Merck, AbbVie, and Johnson & Johnson
NEW YORK, March 7, 2017 /PRNewswire/ --
This morning, Stock-Callers.com has lined up for evaluation these four major players within the Drug Manufacturers industry: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). These companies operate in the Healthcare sector, which was moderately lower late Monday, March 06th, 2017, with the NYSE Health Care Index posting a 0.3% retreat, while shares of health care companies in the S&P 500 were down about 0.2% as a group. You can access our complimentary research reports on these stocks now at:
Shares in New York headquartered Pfizer Inc. saw a slight decline of 0.49%, ending Monday's trading session at $34.35. The stock recorded a trading volume of 18.19 million shares. The Company's shares have gained 8.26% in the last one month, 10.30% over the previous three months, and 6.83% on an YTD basis. The stock is trading 5.60% and 3.90% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 70.36.
On March 06th, 2017, Bristol-Myers Squibb Company and Pfizer announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66th Annual Scientific Session, taking place March 17th -19th in Washington, D.C. Visit us today and download your complete report on PFE for free at:
Kenilworth, New Jersey headquartered Merck & Co. Inc.'s stock declined 0.17%, closing the day at $66.47, with a total trading volume of 6.77 million shares. The Company's shares have advanced 3.57% in the past month, 10.24% in the previous three months, and 12.91% since the start of this year. The stock is trading 6.11% above its 50-day moving average and 10.05% above its 200-day moving average. Additionally, shares of Merck & Co., which provides healthcare solutions worldwide, have an RSI of 68.22.
On March 06th, 2017, Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type-2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA® (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin. The Prescription Drug User Fee Act (PDUFA) action date from the FDA is in December 2017 for the three NDAs. Additionally, the European Medicines Agency (EMA) has validated for review three Marketing Authorization Applications for ertugliflozin monotherapy and the two fixed-dose combination products. The complimentary research report on MRK can be accessed at:
On Monday, shares in North Chicago, Illinois-based AbbVie Inc. recorded a trading volume of 6.84 million shares. The stock ended the day 0.33% higher at $63.55. The Company's shares have advanced 4.37% in the past month, 8.50% in the previous three months, and 2.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.20% and 3.39%, respectively. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 66.90.
On February 27th, 2017, AbbVie announced that the European Committee for Medicinal Products for Human Use (CHMP) of EMA has granted a positive opinion for a shorter, eight-week treatment of VIEKIRAX® + EXVIERA® as an option for previously untreated adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and minimal to moderate fibrosis. VIEKIRAX + EXVIERA is currently approved in the European Union for use as a 12-week treatment for GT1b chronic HCV-infected patients without cirrhosis or with compensated cirrhosis. Register for free on Stock-Callers.com and download the PDF research report on ABBV at:
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock declined 0.06%, finishing yesterday's session at $123.71, with a total trading volume of 6.67 million shares. The Company's shares have advanced 9.65% in the last one month, 11.81% in the previous three months, and 8.09% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.10% and 6.65%, respectively. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 80.67.
On February 27th, 2017, Johnson & Johnson announced it has completed the acquisition of Abbott Medical Optics, a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced September 16th, 2016, and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. These product lines will now join with the Company's world-leading ACUVUE® Brand Contact Lenses business. Get free access to your research report on JNJ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA